These important results demonstrate that administration of a single low-dose of VEGFC mRNA-LNPs is an efficient strategy to induce the formation of functional lymphatic vessels, which then reverse the development and progression of secondary lymphedema (Figs. 9–10). The gene discussed is VEGFC; the disease is lymphedema.